Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide first isolated from rabbit cerebral venous blood in 1974 by the Schoenenberger-Monnier group at the University of Basel. The researchers were seeking a transferable sleep factor — a substance that could be isolated from sleeping donors and induce sleep in recipient animals — and found that infusion of the isolated fraction into recipient rabbits reliably produced spindle and delta EEG activity characteristic of deep non-REM sleep. The resulting nonapeptide, DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), has since been studied across a remarkable breadth of biological systems: sleep architecture, neuroendocrine regulation, stress physiology, opioid system modulation, and pain research. This review summarizes the key findings. All content is for educational and research purposes only.

Molecular Profile

DSIP is a nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), with a molecular weight of approximately 849 Da. Its relatively small size places it among the lightest characterized neuropeptides. The peptide is synthesized in the hypothalamus and is found at detectable concentrations in many tissues and biological fluids — including blood, CSF, urine, and breast milk — suggesting it functions as both a neuropeptide and a circulating hormonal signal.

DSIP-like immunoreactivity (DSIP-LI) has been detected in neurons of multiple hypothalamic nuclei, the pituitary gland, the gut, and peripheral endocrine organs. This wide distribution complicates simple receptor mapping but is consistent with DSIP’s diverse reported biological activities. Despite decades of research, a specific high-affinity DSIP receptor remains incompletely characterized, which has led some researchers to propose that DSIP’s effects may be mediated partly through interaction with other receptor systems (including opioid and glutamate receptors) rather than exclusively via a dedicated receptor.

Key Parameters: – Sequence: WAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) – Molecular weight: ~849 Da – Endogenous source: synthesized in hypothalamus; found in blood and CSF – CAS Number: 62568-57-4

Discovery and Sleep Architecture Research

The original characterization of DSIP’s sleep-promoting properties established its core scientific identity. In the initial studies, DSIP infused into rabbit cerebral ventricles produced a significant increase in delta-wave (slow-wave) sleep — the deepest stage of non-REM sleep associated with physical restoration, growth hormone secretion, and memory consolidation — along with reduction in locomotor activity. The effects were observed in rabbits, rats, mice, and, notably, humans, though the cat showed a more pronounced effect on REM sleep (PMID: 6145137).

Subsequent human sleep studies provided mixed but often positive findings. A double-blind controlled trial in chronic insomnia patients found that DSIP administration over multiple consecutive nights was associated with higher sleep efficiency and shorter sleep latency compared to placebo, with one measure of subjectively estimated tiredness also showing improvement in the DSIP group (PMID: 1299794). An earlier study of acute and delayed DSIP effects in human subjects concluded that DSIP was efficacious in sustaining natural sleep functions and was well-tolerated, with no observed psychological, physiological, or biochemical side effects (PMID: 6895513).

These findings positioned DSIP as a candidate endogenous sleep-regulatory factor — distinct from classical hypnotics in that it appeared to modulate rather than artificially induce sleep, working within the framework of normal sleep architecture rather than overriding it.

Neuroendocrine Modulation

Beyond sleep, DSIP has demonstrated a range of neuroendocrine interactions that complicate any simple classification of the peptide as solely a “sleep factor.” Research has shown that DSIP inhibits somatostatin (SRIF) release via a dopaminergic mechanism (PMID: 2886936). Somatostatin is a key hypothalamic inhibitory hormone affecting growth hormone (GH), thyroid-stimulating hormone (TSH), and insulin secretion; DSIP’s capacity to modulate somatostatin tone therefore has indirect effects across multiple endocrine axes.

The peptide has also been shown to influence circadian rhythms of locomotion and intracerebral neurotransmitter concentrations, as well as plasma protein and cortisol concentrations (PMID: 6548970). This broad neuroendocrine footprint suggests that DSIP functions as part of a larger regulatory network governing sleep-wake cycles in the context of hormonal milieu, rather than acting as a simple soporific.

The distribution of DSIP-like immunoreactivity in neurosecretory hypothalamic nuclei — those nuclei involved in releasing hormones into the portal circulation — is consistent with DSIP playing a modulatory role in hypothalamic-pituitary-axis (HPA) regulation. Some researchers have proposed that DSIP functions primarily as a neuromodulator of the HPA axis and circadian system, with sleep induction being one downstream consequence of this broader regulatory role, rather than its primary function.

Stress Response Research

DSIP has been shown to counteract experimentally induced stress situations in animals. Pharmacological studies in rabbits demonstrated that DSIP augmented spindle-dominated, light non-REM sleep and prevented hyposomnia (abnormally reduced sleep) following a stressful situation (PMID: 6548967). This stress-protective effect on sleep architecture is notable: many stressors disrupt sleep by fragmenting non-REM stages and suppressing delta activity, and DSIP appears to buffer this disruption.

This stress-buffering action on sleep extends to findings on circadian rhythm normalization. Stress-induced disruptions of circadian locomotion patterns were partially ameliorated by DSIP in animal models, suggesting the peptide may act at a level of circadian organization upstream of individual behavioral outputs.

The implications for stress physiology research are significant: a neuropeptide that preserves sleep architecture under stressful conditions could be a valuable tool for investigating the neurobiology of stress-sleep interactions, HPA axis regulation, and the mechanisms by which sleep disruption amplifies stress reactivity.

Opioid System Interactions

One of the most pharmacologically interesting dimensions of DSIP research involves its interactions with the endogenous opioid system. DSIP has been shown to stimulate the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro, with findings suggesting that DSIP produces antinociceptive effects by indirectly activating opioid receptors through enkephalin release (PMID: 2706459).

Building on this, clinical research demonstrated that DSIP could be used to treat withdrawal symptoms in opiate-dependent patients, with the proposed mechanism involving agonistic activity at opiate receptors (PMID: 6328354). In this preliminary clinical pilot, DSIP administration was associated with successful management of withdrawal symptoms, supporting the pre-existing preclinical evidence of opioid system cross-talk.

DSIP’s interaction with the opioid system also likely contributes to its effects on pain perception. Therapeutic studies examined DSIP in patients with chronic pronounced pain episodes, with results supporting a modulatory role for the peptide in pain regulation through endogenous opioidergic mechanisms (PMID: 6548970).

Research Significance and Outstanding Questions

Despite decades of investigation, DSIP remains an incompletely understood neuropeptide. A thorough review by Steiger characterizes DSIP as “a still unresolved riddle,” noting that the peptide’s diverse biological activities — spanning sleep, endocrinology, pain, stress, and opioid pharmacology — resist simple classification (PMID: 16539679). This breadth is both a strength (making DSIP relevant across multiple research domains) and a challenge (complicating the identification of primary vs. secondary effects and the delineation of receptor mechanisms).

The peptide continues to be a legitimate research target for investigators studying: – Slow-wave sleep regulation and sleep homeostasis – HPA axis and circadian rhythm interactions – Endogenous opioid system modulation – Neuropeptide-mediated stress buffering

Compound Information

• Chemical Name: Delta Sleep-Inducing Peptide (DSIP)
• Sequence: WAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)
• Molecular Weight: ~849 Da
• Classification: Endogenous nonapeptide; hypothalamic neuropeptide
• CAS Number: 62568-57-4
• Research Storage: Lyophilized powder; stable at −20°C; reconstitute in sterile water or saline for research assays

References

1. Schoenenberger GA, Maier PF, Tobler HJ, et al. Delta-sleep-inducing peptide (DSIP): a review. Pharmacology. 1984;29(4):185-192. PMID:6145137
2. Schneider-Helmert D. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Sleep. 1984;7(3):234-241. PMID:1299794
3. Schoenenberger GA, Schneider-Helmert D, Maier PF. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Res. 1982;2(5-6):397-409. PMID:6895513
4. Steiger A. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Peptides. 2006;27(5):1166-1175. PMID:16539679
5. Iyer KS, McCann SM. Delta sleep inducing peptide inhibits somatostatin release via a dopaminergic mechanism. Brain Res Bull. 1987;19(5):535-538. PMID:2886936
6. Kovalzon VM. Some pharmacological effects of delta-sleep-inducing peptide (DSIP). Peptides. 1984;5(3):519-524. PMID:6548967
7. Nakamura A, Shiomi H. Delta-sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro. Neurosci Lett. 1989;97(1-2):140-144. PMID:2706459
8. Schneider-Helmert D, Gnirss F, Jufer M, et al. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Subst Alcohol Actions Misuse. 1981;2(3):157-162. PMID:6328354
9. Rudolph S, Tobler HJ, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-385. PMID:6548970

Research Use Disclaimer: DSIP (Delta Sleep-Inducing Peptide) is sold by Rejuven8 Peptides strictly for in vitro and preclinical research use only. It is not intended for human consumption, veterinary use, or any therapeutic application. This content is educational and does not constitute medical advice. Always comply with applicable laws and institutional guidelines governing peptide research.

All products are sold for research purposes only. Not for human consumption. These statements have not been evaluated by the FDA. This content is for informational and educational purposes only and does not constitute medical advice.